Sangamo Biosciences (SGMO) Price & Analysis

Compare

2,415 Followers

SGMO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.41 - $3.18

Previous CloseN/A

Volume2.84M

Average Volume (3M)6.71M

Market Cap

$156.89M

Enterprise Value$124.20M

Total Cash (Recent Filing)$38.34M

Total Debt (Recent Filing)$23.46M

Price to Earnings (P/E)―

Beta1.26

Next Earnings

Oct 30, 2025

EPS Estimate

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.08

Shares Outstanding301,709,470

10 Day Avg. Volume4,933,362

30 Day Avg. Volume6,712,186

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.79

Enterprise Value/Revenue1.52

Enterprise Value/Gross Profit1.56

Enterprise Value/Ebitda-2.18

Forecast

1Y Price Target

$3.90

Price Target Upside650.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe registrational Phase 1/2 STAAR trial in Fabry disease has delivered positive top-line results across renal, cardiac, and quality-of-life endpoints.

PartnershipsThe proprietary STAC-BBB capsid has now attracted three blue-chip pharma partnerships, generating $88 million in upfront payments with more than $4.6 billion in potential milestones.

Regulatory PathwaySGMO announced alignment with FDA on a regulatory pathway to accelerated filing for their AAV-based GTx '920 for Fabry disease.

Bears Say

Financial PerformanceSGMO reported a net loss of ~$20M.

RisksRisks include clinical development risk tied to isa-vec, commercialization risk, and reimbursement risk among others.

Sangamo Biosciences News

Sangamo Biosciences: Poised for Significant Value Creation with Promising Clinical Trials and Strategic Partnerships

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Sangamo Biosciences, retaining the price target of...

20d ago

SGMO

Sangamo Biosciences: Cautious Optimism in Earnings Call

Sangamo Biosciences (($SGMO)) has held its Q2 earnings call. Read on for the main highlights of the call....

21d ago

SGMO

Sangamo Biosciences: Strategic Positioning and Growth Potential Drive Buy Rating

TD Cowen analyst Ritu Baral has maintained their bullish stance on SGMO stock, giving a Buy rating on...

21d ago

SGMO

Sangamo Therapeutics Reports Strong Q2 2025 Results

Sangamo Biosciences ( ($SGMO) ) has released its Q2 earnings. Here is a breakdown of the information Sangamo...

24d ago

SGMO

SGMO Earnings this Week: How Will it Perform?

Sangamo Biosciences (SGMO) is scheduled to report 2nd quarter earnings on 08/07/2025, after the market closes. Regarding Q2...

27d ago

SGMO

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Sangamo (SGMO) 1.72% +0.48,...

1M ago

CAN

Unusually active option classes on open July 24th

Unusual total active option classes on open include: Sangamo (SGMO), American Eagle (AEO), DIREXION DAILY GOOGL BULL 1.5X...

1M ago

AEO

Cautious Optimism for Sangamo Biosciences Amid Promising Fabry Program Data and Ongoing Business Developments

In a report released on June 25, Yanan Zhu from Wells Fargo maintained a Hold rating on Sangamo...

2M ago

SGMO

Sangamo Announces Positive Results for Fabry Disease Therapy

Sangamo Biosciences ( ($SGMO) ) has shared an update. On June 24, 2025, Sangamo Therapeutics, Inc. announced positive...

2M ago

SGMO

Sangamo announces topline results from STAAR study

Sangamo (SGMO) announced topline results from the registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a...

2M ago

SGMO

Sangamo Biosciences Approves Amendments to Equity Plan

Sangamo Biosciences ( ($SGMO) ) has issued an update. On June 12, 2025, Sangamo Therapeutics, Inc. held its...

3M ago

SGMO

Sangamo Biosciences: Promising Strategic Milestones and Potential Value Creation Drive Buy Rating

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and...

3M ago

SGMO

Sangamo Biosciences’ Earnings Call: Progress Amid Challenges

Sangamo Biosciences (($SGMO)) has held its Q1 earnings call. Read on for the main highlights of the call....

4M ago

SGMO

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

4M ago

BMY

ABBV

SGMO FAQ

What was Sangamo Biosciences’s price range in the past 12 months?

Sangamo Biosciences lowest stock price was $0.41 and its highest was $3.18 in the past 12 months.

What is Sangamo Biosciences’s market cap?

Sangamo Biosciences’s market cap is $156.89M.

When is Sangamo Biosciences’s upcoming earnings report date?

Sangamo Biosciences’s upcoming earnings report date is Oct 30, 2025 which is in 59 days.

How were Sangamo Biosciences’s earnings last quarter?

Sangamo Biosciences released its earnings results on Aug 07, 2025. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.01 by -$0.07.

Is Sangamo Biosciences overvalued?

According to Wall Street analysts Sangamo Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sangamo Biosciences pay dividends?

Sangamo Biosciences does not currently pay dividends.

What is Sangamo Biosciences’s EPS estimate?

Sangamo Biosciences’s EPS estimate is 0.

How many shares outstanding does Sangamo Biosciences have?

Sangamo Biosciences has 301,709,470 shares outstanding.

What happened to Sangamo Biosciences’s price movement after its last earnings report?

Sangamo Biosciences reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.01. Following the earnings report the stock price went down -4.167%.

Which hedge fund is a major shareholder of Sangamo Biosciences?

Currently, no hedge funds are holding shares in SGMO

Sangamo Biosciences Stock Smart Score

Underperform

Fundamentals

Return on Equity

-298.41%

Trailing 12-Months

Asset Growth

4.89%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sangamo Biosciences

Sangamo Biosciences, Inc. (SGMO) is a clinical-stage biotechnology company focused on developing innovative genetic therapies to treat severe diseases. The company leverages its proprietary gene editing platform, which includes zinc finger protein (ZFP) technology, to create targeted therapies for genetic disorders, hemophilia, and other diseases. Sangamo operates primarily in the fields of gene therapy, gene regulation, and cell therapy, and is committed to advancing its pipeline of product candidates through clinical trials and partnerships.

Sangamo Biosciences (SGMO) Earnings & Revenues

Historic Earnings Reports

SGMO Company Deck

SGMO Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant achievements in advancing their clinical and preclinical pipeline, particularly with positive results in the STAAR study for Fabry disease and progress in neurology and prion disease programs. Despite these advancements, challenges remain, including the need to secure additional funding and a Fabry commercialization partner. The sentiment is generally positive but tempered by financial uncertainties.View all SGMO earnings summaries

SGMO Stock 12 Month Forecast

Average Price Target

$3.90

▲(650.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.56,1.2861538461538462,2.0123076923076924,2.7384615384615385,3.4646153846153847,4.190769230769231,4.9169230769230765,5.643076923076924,6.36923076923077,7.095384615384615,7.821538461538461,8.547692307692309,9.273846153846154,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.56,0.816923076923077,1.073846153846154,1.330769230769231,1.5876923076923077,1.8446153846153845,2.1015384615384614,2.3584615384615386,2.6153846153846154,2.8723076923076922,3.129230769230769,3.3861538461538463,3.643076923076923,{"y":3.9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.56,0.5553846153846155,0.5507692307692308,0.5461538461538462,0.5415384615384615,0.536923076923077,0.5323076923076924,0.5276923076923077,0.5230769230769231,0.5184615384615385,0.5138461538461538,0.5092307692307693,0.5046153846153846,{"y":0.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.7,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.82,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.57,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.47,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.56,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >